Marvell-Lumentum Deal Reportedly Set to Avoid Large Premium
A muted takeover premium could temper Lumentum shareholder enthusiasm and reshape merger-arbitrage expectations around the reported Marvell deal.
FDA Delays Mitapivat Sickle Cell Decision Until February 2027
The FDA extended its mitapivat review to February 2027, pushing a key regulatory and commercial cata…
Sun Pharma’s Ilumya Wins FDA Approval for Psoriatic Arthritis
FDA approval for Ilumya in active psoriatic arthritis broadens Sun Pharma’s U.S. immunology opportun…
NRx Pharmaceuticals Shares Jump 15% After Early FDA Approval for Preservative-Free Ketamine
NRx Pharmaceuticals won early FDA approval for preservative-free ketamine, sending NRXP shares appro…
Mineralys’ Positive CKD Data Expands the Investment Case for Lorundrostat
Positive Phase 2 CKD data may broaden lorundrostat’s commercial potential and sharpen investor inter…
SELLAS AML Trial Milestone Brings SLS Shares Closer to a High-Stakes Data Readout
SELLAS says its Phase 3 REGAL trial reached a statistical milestone, setting up preliminary topline …
Geron’s Imetelstat Myelofibrosis Trial Puts a Major Biotech Catalyst Back in Focus
Geron’s Phase 3 IMpactMF update places imetelstat at the center of a potentially binary catalyst for…
Lumentum Shares Jump on Reported Marvell Acquisition Talks
Lumentum shares rose after a report said Marvell was in advanced talks to acquire the optical-compon…
Kymera Therapeutics Sets Up Year-End Catalyst With KT-621 Data on Deck
Kymera’s third-quarter update pairs positive KT-579 Phase 1 results with a year-end 2026 KT-621 Phas…
Iovance Stock Jumps as Lifileucel Combination Delivers 62.5% Response Rate
Iovance’s frontline melanoma data could broaden lifileucel’s opportunity, but the result is not yet …